GSE74383 ROR2 overexpression MCF-7 1 v 3 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE74383_ROR2 overexpression_MCF-7_1_v_3_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE74383_ROR2 overexpression_MCF-7_1_v_3_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE74383_ROR2 overexpression_MCF-7_1_v_3_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE74383_ROR2 overexpression_MCF-7_1_v_3_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

PCDHB1 antisense RNA 1

Gene

DSCAM antisense RNA 1

Gene

LIFR antisense RNA 1

Gene

small Cajal body-specific RNA 6

Gene

RNF32 antisense RNA 1

Gene

ANKRD30B pseudogene 1

Gene

uncharacterized LOC124903134

Gene

RNA, 7SL, cytoplasmic 33, pseudogene

Gene

ribosomal protein S6 pseudogene 24

Gene

hes related family bHLH transcription factor with YRPW motif 2

  • Gene

    PCDHB1 antisense RNA 1


  • Gene

    DSCAM antisense RNA 1


  • Gene

    LIFR antisense RNA 1


  • Gene

    small Cajal body-specific RNA 6


  • Gene

    RNF32 antisense RNA 1


  • Gene

    ANKRD30B pseudogene 1


  • Gene

    uncharacterized LOC124903134


  • Gene

    RNA, 7SL, cytoplasmic 33, pseudogene


  • Gene

    ribosomal protein S6 pseudogene 24


  • Gene

    hes related family bHLH transcription factor with YRPW motif 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.